India approves generic lenacapavir, an HIV‑prevention shot, for low‑income countries
Summary
- The Drug Controller General of India (DCGI) granted approval to the generic version of lenacapavir, a long‑acting HIV‑prevention injectable.
- Lenacapavir, originally developed by Gilead Sciences, can be administered every six months, offering a convenient alternative to daily oral PrEP.
- The approved generic is expected to be manufactured domestically and become available in certain markets within weeks, significantly lowering the cost of HIV prevention.
- India aims to supply the affordable generic to low‑income and middle‑income countries, enhancing global HIV‑prevention efforts.
- The move underscores India's growing role in the production of high‑value biologics and its contribution to global health security.
Key Facts
- · Drug: lenacapavir (generic version) approved for HIV prevention.
- · Administration: injectable, effective for six months per dose.
- · Approval authority: Drug Controller General of India (DCGI).
- · Availability: expected within weeks in select markets.
- · Cost advantage: generic pricing to make it affordable for low‑income countries.
- · Original developer: Gilead Sciences (USA).
- · India's goal: supply to low‑ and middle‑income nations to curb HIV spread.
Why it matters
Affordable, long‑acting HIV‑prevention injectables can dramatically increase access in resource‑constrained settings, helping India fulfil its commitment to global health equity and positioning its pharmaceutical sector as a key player in combating the HIV epidemic worldwide.
#HIV#lenacapavir#generic drugs#India#low‑income countries#public health